ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      59,985.77
      1.27%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Aeterna Zentaris Inc (AEZS)

      7. Aeterna Zentaris Inc (AEZS) News

      AEZS

      Aeterna Zentaris (AEZS)

      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:AEZS
      DateTimeSourceHeadlineSymbolCompany
      02/24/20057:30AMPR Newswire (US)Appointments to AEterna Zentaris Scientific Advisory BoardNASDAQ:AEZS
      02/22/20057:31AMPR Newswire (US)AEterna Zentaris Announces 2004 Fourth Quarter and Full Year Financial Results Conference Call and WebcastNASDAQ:AEZS
      02/17/20059:28AMPR Newswire (US)AEterna Zentaris Subsidiary Atrium Biotechnologies Files Preliminary Prospectus for Initial Public OfferingNASDAQ:AEZS
      02/14/200510:26AMPR Newswire (US)AEterna Zentaris to Present at Upcoming Bio CEO and Wells Fargo Conferences in New York CityNASDAQ:AEZS
      01/25/20057:30AMPR Newswire (US)AEterna Zentaris Subsidiary Atrium Biotechnologies Acquires Canadian Business MultichemNASDAQ:AEZS
      01/18/20057:32AMPR Newswire (US)AEterna Zentaris Advances AN-152 Targeted Anti-Cancer Agent into Clinical DevelopmentNASDAQ:AEZS
      01/06/20057:30AMPR Newswire (US)AEterna Zentaris Strengthens its Position in the Development of Innovative Signal Transduction Inhibitors as a Potential Way toNASDAQ:AEZS
      12/22/20045:58PMPR Newswire (US)AEterna Zentaris Grants its Subsidiary Atrium Biotechnologies Marketing Rights for NeovastatNASDAQ:AEZS
      12/15/20047:31AMPR Newswire (US)AEterna Zentaris Announces Appointments to its Board, as well as to the Board and Management of its Subsidiary Atrium BiotechnolNASDAQ:AEZS
      12/06/20047:30AMPR Newswire (US)AEterna Zentaris Receives Regulatory Approval for Impavido(R) in GermanyNASDAQ:AEZS
      11/15/20047:33AMPR Newswire (US)Clinical Experience on AEterna Zentaris' Impavido(R) Published in Clinical Infectious DiseasesNASDAQ:AEZS
      11/04/20047:32AMPR Newswire (US)AEterna Zentaris Reports Third Quarter 2004 Financial and Operating ResultsNASDAQ:AEZS
      10/28/20048:31AMPR Newswire (US)AEterna Zentaris Announces Third Quarter Financial Results Conference Call and WebcastNASDAQ:AEZS
      10/27/20048:31AMPR Newswire (US)AEterna Zentaris Enters into a License and Collaboration Agreement with Tulane University for a Novel Class of Potential Anti-CaNASDAQ:AEZS
      10/20/20048:31AMPR Newswire (US)AEterna Zentaris to Present at Two Upcoming Conferences in the United States and GermanyNASDAQ:AEZS
      10/07/20048:30AMPR Newswire (US)AEterna Zentaris Reports Statistically Significant Positive Phase II Data on Cetrorelix in Benign Prostatic HyperplasiaNASDAQ:AEZS
      10/06/20048:31AMPR Newswire (US)AEterna Zentaris to Present at Upcoming Investment Conferences in San Francisco and Quebec CityNASDAQ:AEZS
      09/30/20049:50AMPR Newswire (US)Data from Perifosine Phase II Single-Agent Soft Tissue Sarcoma Study Presented at the 16th Annual EORTC-NCI-AACR ConferenceNASDAQ:AEZS
      09/30/20049:40AMPR Newswire (US)Data From KRX-0401 (Perifosine) Phase II Single-Agent Soft-Tissue Sarcoma Study Presented at the 16th Annual EORTC-NCI-AACR ConfNASDAQ:AEZS
      09/27/20048:31AMPR Newswire (US)AEterna Zentaris to Present New in vitro Data on Antiangiogenic Properties of Perifosine at Strategic Research Institute's AngioNASDAQ:AEZS
      09/23/20048:31AMPR Newswire (US)AEterna Zentaris to Present at Upcoming Scientific and Investment ConferencesNASDAQ:AEZS
      09/07/20048:32AMPR Newswire (US)AEterna Zentaris to Present at Orion Healthcare Conference September 13 in TorontoNASDAQ:AEZS
      08/12/200410:15AMPR Newswire (US)AEterna Zentaris Enters a License and Collaboration Agreement with Spectrum Pharmaceuticals on Fourth Generation LHRH AntagonistNASDAQ:AEZS
      08/12/20049:30AMPR Newswire (US)Spectrum Pharmaceuticals Licenses a Fourth-Generation Phase 2 LHRH Antagonist From Zentaris GmbHNASDAQ:AEZS
      08/11/20048:50AMPR Newswire (US)AEterna Zentaris Reports Second Quarter 2004 Financial and Operating ResultsNASDAQ:AEZS
      08/04/20049:29AMPR Newswire (US)Keryx Biopharmaceuticals, Inc. Initiates First Chemotherapy Combination Study for KRX-0401 (Perifosine)NASDAQ:AEZS
      08/04/20048:31AMPR Newswire (US)AEterna Zentaris Announces Second Quarter Financial Results Conference Call and WebcastNASDAQ:AEZS
      06/07/200410:22AMPR Newswire (US)Investigators from the Netherlands Cancer Institute Report Encouraging Results from Phase I Trial of KRX-0401 (Perifosine) in CoNASDAQ:AEZS
      06/07/200410:21AMPR Newswire (US)AEterna Zentaris Reports Encouraging Results from Phase I Trial of Perifosine in Combination with Radiotherapy at the 2004 AmeriNASDAQ:AEZS
      06/03/20048:31AMPR Newswire (US)AEterna Zentaris to Present at Three Upcoming Conferences: ASCO, BIO 2004 and Needham Biotechnology ConferenceNASDAQ:AEZS
       Showing the most relevant articles for your search:NASDAQ:AEZS